齐拉西酮片联合氯氮平治疗难治性精神分裂症疗效及对认知功能的影响
Clinical efficacy of ziprasidone combined with clozapine in the treatment of refractory schizophrenia and its effect on cognitive function
ES评分 0
| DOI |
| 刊名 |
Journal of International Psychiatry
|
| 年，卷(期) |
2019, 46(2) |
| 作者 |
|
| 作者单位 |
郑州市第八人民医院 ;
|
| 摘要 |
摘要 目的: 旨在观察齐拉西酮片联合氯氮平治疗难治性精神分裂症疗效及对认知功能的影响。方法:选择2016年9月~2017年9月我院收治的120例难治性精神分裂症患者，将患者随机分为对照组、观察组。对照组患者采用氯氮平治疗，观察组在对照组的基础上使用齐拉西酮片。比较两组患者的疗效和认知功能。结果: 观察组总临床有效率明显优于对照组（93.33% vs 80.00%）（χ2=4.615，P=0.032）；与治疗前做比较，治疗第4周末时观察组与对照组患者的PANSS总分以及阳性症状、阴性症状、一般病理得分均有下降，且在治疗第12周末，各项评分均有显著下降（P<0.05）；与对照组比较，治疗第12周末观察组的PANSS总分及各因子分下降幅度更大（P<0.05）。与治疗前相比，治疗后观察组患者的WAIS-RC各评分明显上升（P<0.05），观察组患者治疗后知识、相似性、数字广度、图画填充、记忆商数评分均优于对照组（P<0.05）；治疗期间观察组与对照组患者的不良反应率无明显差异（P>0.05）。结论：齐拉西酮片联合氯氮平治疗可以改善难治性精神分裂症患者的认知功能，临床疗效显著且安全性较高。
|
| Abstract |
Abstract Objective: To investigate the clinical efficacy of ziprasidone combined with clozapine in the treatment of refractory schizophrenia and its effect on cognitive function. Methods: 120 patients with refractory schizophrenia in our hospital from September 2016 to September 2017 were selected. They were randomly divided into control group and observation group. The control group was treated with clozapine, and the observation group was treated with ziprasidone on the basis of the control group. The efficacy and cognitive function of the two groups were compared. Results: The total clinical efficiency of the observation group was significantly better than that of the control group (93.33% vs 80%) (χ2=4.615, P=0.032). Compared with before treatment, the total score of PANSS, positive symptoms, negative symptoms and general pathological scores in the observation group and the control group decreased at the end of the fourth week of treatment, and the scores of all the scores were significantly decreased at the end of the twelfth week treatment (P<0.05). Compared with the control group, the decreased degree of the total score of PANSS and the scores of each factors in the observation group at the end of the twelfth weekend were significantly greater(P<0.05). Compared with before treatment, the WAIS-RC scores of the observation group were significantly increased after treatment (P<0.05). The knowledge, similarity, digital breadth, picture filling and memory quotient score of the observation group were better than those of the control group (P<0.05). There was no significant difference in the rate of adverse reaction between the observation group and the control group (P>0.05). Conclusion: Ziprasidone combined with clozapine can improve cognitive function in patients with refractory schizophrenia, and the clinical effect is significant and safe.
|
| 基金项目 |
|
| 页码 |
260-262 |
王俊*.
齐拉西酮片联合氯氮平治疗难治性精神分裂症疗效及对认知功能的影响 [J].
国际精神病学杂志.
2019; 46; (2).
260 - 262.